|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Supplementary Table 2. Top metabolites associated with gastric cancer risk: sensitivity analysis without adjusting for time to last meal and glucose levels | | | | |
| Metabolites | SUPER.PATHWAY | SUB.PATHWAY | OR (95%CI) | P |
| orotate | Nucleotide | Pyrimidine Metabolism, Orotate containing | 1.52 (1.20-1.92) | 0.000469 |
| sphinganine | Lipid | Sphingolipid Synthesis | 1.53 (1.23-1.89) | 0.000104 |
| 1-(1-enyl-stearoyl)-GPE (P-18:0) | Lipid | Lysoplasmalogen | 1.54 (1.23-1.92) | 0.000144 |
| 1-(1-enyl-palmitoyl)-GPE (P-16:0) | Lipid | Lysoplasmalogen | 1.50 (1.22-1.86) | 0.000164 |
| glycerophosphoethanolamine | Lipid | Phospholipid Metabolism | 1.56 (1.23-1.98) | 0.000231 |
| N6-methyllysine | Amino Acid | Lysine Metabolism | 1.43 (1.17-1.76) | 0.000618 |
| glutamate | Amino Acid | Glutamate Metabolism | 1.48 (1.18-1.85) | 0.000667 |
| 5alpha-pregnan-3beta, 20beta-diol monosulfate | Lipid | Progestin Steroids | 1.45 (1.17-1.79) | 0.000784 |
| 5alpha-pregnan-diol disulfate | Lipid | Progestin Steroids | 1.41 (1.13-1.76) | 0.002264 |
| 1-(1-enyl-oleoyl)-2-docosahexaenoyl-GPE (P-18:1/22:6) | Lipid | Plasmalogen | 1.33 (1.08-1.65) | 0.008750 |
| methylmalonate (MMA) | Lipid | Fatty Acid Metabolism (also BCAA Metabolism) | 1.33 (1.08-1.64) | 0.008454 |
| 1-stearoyl-GPC (18:0) | Lipid | Lysophospholipid | 1.33 (1.07-1.66) | 0.009527 |
| 1-palmitoyl-GPC (16:0) | Lipid | Lysophospholipid | 1.39 (1.12-1.73) | 0.003352 |
| cysteine | Amino Acid | Methionine, Cysteine, SAM and Taurine Metabolism | 0.77 (0.62-0.94) | 0.012075 |
| 1-(1-enyl-palmitoyl)-GPC (P-16:0) | Lipid | Lysoplasmalogen | 1.28 (1.04-1.56) | 0.018764 |
| quinate | Xenobiotics | Food Component/Plant | 0.79 (0.64-0.99) | 0.038706 |
| 3-hydroxypyridine sulfate | Xenobiotics | Chemical | 0.78 (0.62-0.99) | 0.038684 |
| N-(2-furoyl) glycine | Xenobiotics | Food Component/Plant | 0.91 (0.74-1.12) | 0.377377 |
| Adjusted for BMI, smoking status, income, HP infection status (combined biomarker), gastritis, and family history of gastric cancer, in addition to matching variables (age [± 2 years], gender, date of sample collection [± 30 days], time of sample collection [morning or afternoon], recent antibiotic use [yes, no], and menopausal status [for SWHS]). | | | | |